Clin Cancer Res: Compared with placebo, levatinib prolonged the survival time of Chinese patients with radioiodine refractory thyroid cancer by about 6 times!

In the international phase 3 SELECT study, levatinib demonstrated its effectiveness in the treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC); however, levatinib was used for radioactive iodine refractory differentiation in China There is no relevant research on the efficacy in patients with type thyroid cancer
.

The purpose of this study was to evaluate the effectiveness and safety of lenvatinib in Chinese patients with radioactive iodine refractory differentiated thyroid cancer

The confirmed Chinese radioactive iodine refractory differentiated thyroid cancer patients (n=151) were randomized (2:1) to the lenvatinib group (n=103, 24 mg/day) or placebo group (n=48) ), 28 days is a course of treatment
.

The primary endpoint is progression-free survival (PFS), and secondary endpoints include objective response rate and safety

Progression-free survival in both groups

Progression-free survival in both groups

In this study, the progression-free survival of the lenvatinib group was significantly longer than that of the placebo group, which was equivalent to a nearly 6-fold increase (median PFS: 23.
9 vs 3.
7 months; hazard ratio [HR] 0.
16, 95% CI 0.
10 -0.
26; P<0.
0001)
.

The objective response rates of the lenvatinib group and the placebo group were 69.

Le Laval for progression-free survival was significantly longer than that Nigeria placebo group, equivalent to extend nearly six times Le Laval for progression-free survival was significantly longer than that Nigeria placebo group, the equivalent of nearly six times to extend the music cutting imatinib The objective response rates of the placebo group and the placebo group were 69.

The occurrence of adverse events in the two groups

The occurrence of adverse events in the two groups

At the cut-off date, 60.
2% of patients treated with lenvatinib were still continuing treatment; 8.
7% of patients stopped levatinib due to adverse events requiring urgent treatment
.

Overall, 87.

All in all, the initial dose of 24 mg/day of lenvatinib can significantly improve the progression-free survival and objective remission rate of Chinese patients with radioactive iodine refractory differentiated thyroid cancer
.

And no new or unexpected toxic events occurred

The initial dose of 24 mg/day of lenvatinib can significantly improve the progression-free survival and objective response rate of Chinese patients with radioiodine refractory differentiated thyroid cancer.

Original source:

Xiangqian Zheng, et al.

A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer in this message